Hims & Hers Health (NYSE:HIMS) CEO Sells $3,292,612.70 in Stock

Key Points

• Hims & Hers Health CEO Andrew Dudum sold 65,110 shares for over $3.29 million, marking a 40.59% decrease in his position.
• The company's stock price rose by 2.7% to $57.74, with a market cap of $13.05 billion and a P/E ratio of 72.18.
• Hims & Hers Health's latest quarterly earnings showed a revenue of $544.83 million, missing expectations, but representing a 72.6% year-over-year increase.

Hims & Hers Health, Inc. (NYSE:HIMS - Get Free Report) CEO Andrew Dudum sold 65,110 shares of Hims & Hers Health stock in a transaction dated Wednesday, September 17th. The shares were sold at an average price of $50.57, for a total value of $3,292,612.70. Following the completion of the transaction, the chief executive officer directly owned 95,315 shares in the company, valued at $4,820,079.55. This represents a 40.59% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Andrew Dudum also recently made the following trade(s):

• On Tuesday, September 16th, Andrew Dudum sold 47,534 shares of Hims & Hers Health stock. The shares were sold at an average price of $53.27, for a total transaction of $2,532,136.18.
• On Tuesday, September 16th, Andrew Dudum sold 128,127 shares of Hims & Hers Health stock. The stock was sold at an average price of $53.48, for a total transaction of $6,852,231.96.
• On Monday, August 18th, Andrew Dudum sold 128,127 shares of Hims & Hers Health stock. The shares were sold at an average price of $45.06, for a total transaction of $5,773,402.62.
• On Thursday, August 7th, Andrew Dudum sold 660,000 shares of Hims & Hers Health stock. The stock was sold at an average price of $50.58, for a total transaction of $33,382,800.00.
• On Monday, July 21st, Andrew Dudum sold 125,335 shares of Hims & Hers Health stock. The shares were sold at an average price of $49.54, for a total value of $6,209,095.90.
• On Wednesday, July 16th, Andrew Dudum sold 47,534 shares of Hims & Hers Health stock. The shares were sold at an average price of $50.25, for a total value of $2,388,583.50.
• On Wednesday, July 16th, Andrew Dudum sold 2,792 shares of Hims & Hers Health stock. The stock was sold at an average price of $50.58, for a total value of $141,219.36.

Hims & Hers Health Stock Down 0.1%

Shares of HIMS stock traded down $0.05 during trading hours on Monday, reaching $57.77. The company had a trading volume of 18,693,929 shares, compared to its average volume of 27,452,044. The company has a market capitalization of $13.06 billion, a P/E ratio of 72.21, a price-to-earnings-growth ratio of 3.91 and a beta of 2.14. The company has a debt-to-equity ratio of 1.72, a quick ratio of 4.46 and a current ratio of 4.98. Hims & Hers Health, Inc. has a twelve month low of $16.05 and a twelve month high of $72.98. The stock's fifty day simple moving average is $50.83 and its 200 day simple moving average is $45.92.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last released its quarterly earnings results on Monday, August 4th. The company reported $0.17 EPS for the quarter, missing the consensus estimate of $0.18 by ($0.01). Hims & Hers Health had a return on equity of 26.26% and a net margin of 9.63%.The company had revenue of $544.83 million for the quarter, compared to analyst estimates of $550.06 million. During the same period last year, the firm posted $0.06 earnings per share. The business's revenue was up 72.6% on a year-over-year basis. Hims & Hers Health has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS. As a group, sell-side analysts expect that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research firms recently weighed in on HIMS. Zacks Research lowered shares of Hims & Hers Health from a "strong-buy" rating to a "hold" rating in a report on Tuesday, August 19th. Citigroup reaffirmed a "sell" rating on shares of Hims & Hers Health in a research report on Monday, June 23rd. Wall Street Zen downgraded Hims & Hers Health from a "buy" rating to a "hold" rating in a report on Monday, July 28th. Needham & Company LLC restated a "hold" rating on shares of Hims & Hers Health in a report on Tuesday, August 5th. Finally, UBS Group set a $30.00 target price on Hims & Hers Health in a research note on Monday, June 23rd. Two analysts have rated the stock with a Buy rating, eight have given a Hold rating and three have assigned a Sell rating to the stock. Based on data from MarketBeat, Hims & Hers Health has a consensus rating of "Reduce" and an average target price of $38.92.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in HIMS. Virtus Advisers LLC acquired a new stake in shares of Hims & Hers Health during the 2nd quarter valued at approximately $26,000. Quaker Wealth Management LLC acquired a new stake in shares of Hims & Hers Health during the second quarter worth $29,000. Bessemer Group Inc. lifted its position in shares of Hims & Hers Health by 105.8% in the 2nd quarter. Bessemer Group Inc. now owns 607 shares of the company's stock worth $30,000 after buying an additional 312 shares during the last quarter. Skandinaviska Enskilda Banken AB publ boosted its holdings in shares of Hims & Hers Health by 408.2% in the 2nd quarter. Skandinaviska Enskilda Banken AB publ now owns 747 shares of the company's stock valued at $37,000 after buying an additional 600 shares during the period. Finally, Spire Wealth Management bought a new stake in shares of Hims & Hers Health during the 2nd quarter valued at about $42,000. Institutional investors and hedge funds own 63.52% of the company's stock.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.